Deutsche Bank slashes price target on Moderna Inc. [MRNA] – find out why.

Moderna Inc. [NASDAQ: MRNA] closed the trading session at $127.90 on 09/19/22. The day’s price range saw the stock hit a low of $123.6854, while the highest price level was $135.99. The company report on September 12, 2022 that Ministry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna’s Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214.


Top 5 Tech Stocks Every Investor Should Buy Right Now

While finding excellent stocks with the potential for gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Tech Stocks Every Investor Should Buy Right Now", we have identified five tech stocks we believe could appreciate.

Sign up here to get your free report now.

Sponsored


Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a partial change to a new drug application for its Omicron-targeting bivalent COVID-19 booster, mRNA-1273.214 (Spikevax Bivalent Original

“COVID-19 continues to threaten public health in Japan, as infections by Omicron and its subvariants continue. mRNA-1273.214 has demonstrated the ability to trigger significantly higher antibody titers against Omicron BA.1 and BA.4/5 subvariants when compared with mRNA-1273,” said Rami Suzuki, President & Representative Director of Moderna Japan. “We will continue to work with the Ministry of Health, Labour and Welfare to bring this important vaccine to people in Japan as soon as possible to help protect against COVID-19.”.

The stocks have a year to date performance of -49.64 percent and weekly performance of -8.85 percent. The stock has been moved at -28.52 percent over the last six months. The stock has performed -14.73 percent around the most recent 30 days and changed -0.10 percent over the most recent 3-months.

If compared to the average trading volume of 4.87M shares, MRNA reached to a volume of 11408430 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Moderna Inc. [MRNA]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $217.86 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Deutsche Bank have made an estimate for Moderna Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 08, 2022. The new note on the price target was released on February 01, 2022, representing the official price target for Moderna Inc. stock. Previously, the target price had yet another raise to $175, while Deutsche Bank analysts kept a Hold rating on MRNA stock. On January 21, 2022, analysts increased their price target for MRNA shares from 135 to 180.

The Average True Range (ATR) for Moderna Inc. is set at 7.47, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 2.15. The Price to Book ratio for the last quarter was 2.82, with the Price to Cash per share for the same quarter was set at 20.47. Price to Free Cash Flow for MRNA in the course of the last twelve months was 5.36 with Quick ratio for the last quarter at 1.70.

MRNA stock trade performance evaluation

Moderna Inc. [MRNA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -8.85. With this latest performance, MRNA shares dropped by -14.73% in over the last four-week period, additionally sinking by -28.52% over the last 6 months – not to mention a drop of -70.26% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 37.99, with the RSI for the last a single of trading hit 36.08, and the three-weeks RSI is set at 40.07 for Moderna Inc. [MRNA]. The present Moving Average for the last 50 days of trading for this stock 155.87, while it was recorded at 134.44 for the last single week of trading, and 167.86 for the last 200 days.

Moderna Inc. [MRNA]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Moderna Inc. [MRNA] shares currently have an operating margin of +71.89 and a Gross Margin at +84.53. Moderna Inc.’s Net Margin is presently recorded at +66.27.

Return on Equity for this stock inclined to 146.08, with Return on Assets sitting at 75.78.

Moderna Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.70 and a Current Ratio set at 2.00.

Moderna Inc. [MRNA]: Insider Ownership positions

There are presently around $31,285 million, or 64.10% of MRNA stock, in the hands of institutional investors. The top three institutional holders of MRNA stocks are: BAILLIE GIFFORD & CO with ownership of 45,559,791, which is approximately -0.152% of the company’s market cap and around 5.40% of the total institutional ownership; VANGUARD GROUP INC, holding 27,648,457 shares of the stock with an approximate value of $3.54 billion in MRNA stocks shares; and BLACKROCK INC., currently with $3.35 billion in MRNA stock with ownership of nearly -8.561% of the company’s market capitalization.

Positions in Moderna Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 456 institutional holders increased their position in Moderna Inc. [NASDAQ:MRNA] by around 15,771,419 shares. Additionally, 473 investors decreased positions by around 19,641,870 shares, while 171 investors held positions by with 209,195,200 shares. The mentioned changes placed institutional holdings at 244,608,489 shares, according to the latest SEC report filing. MRNA stock had 101 new institutional investments in for a total of 1,814,019 shares, while 116 institutional investors sold positions of 854,770 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here